Clear Street’s Artelo Biosciences ARTL Stock Holding History

Clear Street’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$758	–	1398
2026 Q1	$758	Buy	+11	New	+$468	﹤0.01%	1052

Other funds holding ARTL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RIL

Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Clear Street's ARTL Position: Q2 2026 in Review

Clear Street sold out of Artelo Biosciences (ARTL) in Q2 2026, closing a stake of 11 shares — an estimated $758 sold.

Clear Street first reported a position in ARTL in Q1 2026 and held it in 1 quarter. The position peaked at $758 in Q1 2026. 7 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

Clear Street reported no remaining Artelo Biosciences position as of Q2 2026 after selling out during the quarter.
Clear Street sold 11 Artelo Biosciences shares in Q2 2026, an estimated $758.
Clear Street first reported a position in Artelo Biosciences in Q1 2026 and held it in 1 quarter.
Clear Street's Artelo Biosciences position peaked at $758 in Q1 2026.
7 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.